US 11,850,257 B2
Method for enhancing beta-adrenergic response
Steinthor Sigurdsson, Reykjavik (IS)
Assigned to SAGANATURA EHF., Hafnarfjordur (IS)
Appl. No. 17/429,695
Filed by Saganatura EHF., Hafnarfjördur (IS)
PCT Filed Feb. 11, 2020, PCT No. PCT/IS2020/050001
§ 371(c)(1), (2) Date Aug. 10, 2021,
PCT Pub. No. WO2020/165925, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. EU9111 (IS), filed on Feb. 11, 2019.
Prior Publication US 2022/0202840 A1, Jun. 30, 2022
Int. Cl. A61K 31/7048 (2006.01); A61P 13/10 (2006.01); A61K 9/48 (2006.01); A61K 36/232 (2006.01); A61K 36/234 (2006.01); A61K 36/505 (2006.01)
CPC A61K 31/7048 (2013.01) [A61K 9/48 (2013.01); A61K 36/232 (2013.01); A61K 36/234 (2013.01); A61K 36/505 (2013.01); A61P 13/10 (2018.01)] 7 Claims
 
1. A method of treatment of a urinary condition in a human subject wherein the urinary condition is manifested by an overactive bladder, the method comprising administering to a human subject in need thereof a therapeutically effective dose of cnidimoside A.